7,080
Total Publications
457,261
Total Citations
Top Researchers
- Yi Zhang 97,450 citations • 2216 papers
- Chunsheng Wang 94,696 citations • 776 papers
- Shukui Qin 51,906 citations • 573 papers
- Chunlei Liu 41,520 citations • 606 papers
- Min Wang 40,940 citations • 1144 papers
- Hongbing Shen 40,501 citations • 1136 papers
- Zhen Yan 37,297 citations • 333 papers
- Lihua Zhang 32,958 citations • 1445 papers
- Zhenhai Xia 30,947 citations • 359 papers
- Li Lin 28,946 citations • 1040 papers
Most Cited Papers
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial 2008 • 5,814 citations
- Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study 2011 • 4,083 citations
- Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials 2015 • 1,575 citations
- Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer 2020 • 1,155 citations
- Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study 2021 • 1,066 citations
- Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer 2022 • 1,025 citations
- METTL3-mediated m <sup>6</sup> A modification of HDGF mRNA promotes gastric cancer progression and has prognostic significance 2019 • 943 citations
- Cancer-associated fibroblasts: an emerging target of anti-cancer immunotherapy 2019 • 869 citations
- Stacked Sparse Autoencoder (SSAE) for Nuclei Detection on Breast Cancer Histopathology Images 2015 • 862 citations
- CircRNA: a novel type of biomarker for cancer 2017 • 810 citations